Together, the data support the potential of topical Hsp90 inhibitors like 17-AAG to modulate immune activation, restore barrier function, and normalize the microbiome in AD, offering a promising therapeutic avenue (31). Here, HSP90AA1 is linked to Alzheimer disease.